Loading market dashboard
Curis, Inc.
CRISHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Curis, Inc. (CRIS) Q1 2026 Earnings Call Transcript
Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass.
LEXINGTON, Mass., May 5, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company will report its first quarter 2026 financial and operating results on Tuesday, May 12, 2026, at 4:00 p.m.
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.11 per share a year ago.
Curis (CRIS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Curis, Inc. (CRIS) Q4 2025 Earnings Call Transcript
Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass.
INGOLSTADT, Germany--(BUSINESS WIRE)--SecurityBridge, a leading provider of cybersecurity solutions for SAP, today announced the release of the Cybersecurity Resilience Index for SAP (CRIS), an industry benchmarking report that analyzes how organizations running SAP are securing their environments. The report is a timely response to global security incidents involving SAP environments that provides organizations with key actionable insights into strengths and gaps in their SAP security posture.
LEXINGTON, Mass., March 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company will report its fourth quarter 2025 financial and operating results on Thursday, March 19, 2026, at 4:00 p.m.
